Corcept Therapeutics Incorporated (CORT) Q3 2021 Earnings Call Transcript

Statements during this call, other than statements of historical facts, are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties which may cause actual results to differ materially from those such statements express or imply. The availability of competing treatments, including generic versions of Korlym, our ability to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym, risks related to the development of our product candidates, including their clinical attributes, regulatory approvals, mandates and oversights and other requirements, and the scope and protective power of our intellectual property.